macht mich sehr nachdenklich.
gruß grenke
gruß grenke
Anzeige
Meldung des Tages: +15 % an einem Tag – und dieser Ausbruch hat gerade erst begonnen
Neuester,
zuletzt geles. Beitrag
Antworten | Börsen-Forum Übersicht
Zurück
Weiter
... 14 15 16 18 19 20 ...
Antworten | Börsen-Forum Übersicht
Zurück
Weiter ... 14 15 16 18 19 20 ...
Entweder 10000% oder Totalverlust
Beiträge:
1.626
Zugriffe: 120.555 / Heute: 28
Zugriffe: 120.555 / Heute: 28
|
| ||||||||||||||
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi IBEX 35 Doble Apalancado Diario (2x) UCITS ETF Acc
Perf. 12M: +121,24%
Amundi IBEX 35 UCITS ETF Acc
Perf. 12M: +54,92%
Amundi IBEX 35 UCITS ETF Dist
Perf. 12M: +53,44%
Amundi MSCI Greece UCITS ETF Dist
Perf. 12M: +52,80%
grüß Dich, du geistiger Tiefflieger.
Bleib beim Thema, ich habe gesagt " dicke Gewinne " und die fangen bei mir bei 30-40% an. Keiner hat von reich gesprochen.
gruß hannes
Bleib beim Thema, ich habe gesagt " dicke Gewinne " und die fangen bei mir bei 30-40% an. Keiner hat von reich gesprochen.
gruß hannes
USD 0.073 0.009 +14,06%
OBB Berlin Frankfurt Xetra 18:34 06.01.
Bid 0.071 50
Letzter Umsatz 100.000 Tagesumsatz 7.420.800
Ask 0.073 50
Biotechnologie USA
Chart
Aktuelles
mehr...
Details
Eröffnung 0.068 Schluss 0.064 03.01.
Tageshoch 0.073 52W Hoch 0.077 12.12.
Tagestief 0.067 52W Tief 0.047 23.12.
52W Perf. n.a. Jahreshoch 0.064 03.01.
4W Perf. n.a. Jahrestief 0.054 02.01.
Handelsplätze
Börse Preis Diff Zeit/Datum Vol.
Berlin 0.072 +20,00% 18:32 06.01. 251.690
Frankfurt 0.070 +27,27% 17:56 06.01. 230.319
Xetra 0.10 +0,00% 13:39 15.11. 3.292
gruß hannes
Calypte Receives Exemption from FDA Lot Release Testing; Production-to-Market Time for HIV-1 Urine EIA Test Significantly Reduced
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 8, 2003--Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, today announced receipt of U.S. Food and Drug Administration (FDA) approval to eliminate the lot release testing requirement for the company's HIV-1 Urine EIA test. This change is expected to reduce the production-to-market time by two to eight weeks and decrease associated production costs.
Nancy Katz, president and CEO of Calypte, stated, "The FDA has recognized Calypte's long-term manufacturing consistency, successful facility inspections and the extensive history of quality product performance. The Agency's determination to eliminate product sample submission prior to distribution indicates the FDA's confidence in our manufacturing and testing procedures, as well as our commitment to quality. We believe the elimination of lot release testing will improve our ability to efficiently manufacture products, to effectively satisfy growing product demand and to ensure greater manufacturing and supply predictability."
When the FDA approved the Calypte HIV-1 Urine EIA test in 1996 as a licensed biological product, it required submission of every lot for testing in FDA laboratories before the lot could be released for sale. Since then, Calypte moved its product manufacturing to its Alameda, California facility and secured the FDA pre-market approval (PMA) of the EIA product as a Class III medical device. Calypte submitted the lot exemption request to the FDA in November 2001, supplied additional data in August 2002, and received approval in late December 2002. The information presented to the FDA for its approval included data on 73 finished kit lots with over 400 individual component lots prepared.
In the FDA's approval letter, the Agency encouraged Calypte to seek the same elimination of lot release testing for Calypte's Cambridge Biotech HIV-1 Urine Western Blot, which is now also approved as a Class III medical device. Since this product's initial approval in 1998, it also has been required to undergo lot-by-lot release testing.
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 8, 2003--Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, today announced receipt of U.S. Food and Drug Administration (FDA) approval to eliminate the lot release testing requirement for the company's HIV-1 Urine EIA test. This change is expected to reduce the production-to-market time by two to eight weeks and decrease associated production costs.
Nancy Katz, president and CEO of Calypte, stated, "The FDA has recognized Calypte's long-term manufacturing consistency, successful facility inspections and the extensive history of quality product performance. The Agency's determination to eliminate product sample submission prior to distribution indicates the FDA's confidence in our manufacturing and testing procedures, as well as our commitment to quality. We believe the elimination of lot release testing will improve our ability to efficiently manufacture products, to effectively satisfy growing product demand and to ensure greater manufacturing and supply predictability."
When the FDA approved the Calypte HIV-1 Urine EIA test in 1996 as a licensed biological product, it required submission of every lot for testing in FDA laboratories before the lot could be released for sale. Since then, Calypte moved its product manufacturing to its Alameda, California facility and secured the FDA pre-market approval (PMA) of the EIA product as a Class III medical device. Calypte submitted the lot exemption request to the FDA in November 2001, supplied additional data in August 2002, and received approval in late December 2002. The information presented to the FDA for its approval included data on 73 finished kit lots with over 400 individual component lots prepared.
In the FDA's approval letter, the Agency encouraged Calypte to seek the same elimination of lot release testing for Calypte's Cambridge Biotech HIV-1 Urine Western Blot, which is now also approved as a Class III medical device. Since this product's initial approval in 1998, it also has been required to undergo lot-by-lot release testing.
schon 250000 stck in 15 minuten plus 11%
Aber nach den letzten positiven Meldungen wurden i.d.R. immer sehr schnell Gewinne mitgenommen und CALY stand z.T. schlechter da als vorher!
Bei 0,05 steig ich wieder ein ;-)
Gruß
AUF GEHT`S
Bei 0,05 steig ich wieder ein ;-)
Gruß
AUF GEHT`S
für heute geblieben?
Magere knappe 3% im Plus bei 0,07.
Das ist das Problem bei CALY, wenn die gute News bringen, geht´s eigentlich selten richtig gut ab und nach 2-3 Tagen stehen die wie vorher auch.
Unter 0,05 kaufe ich wieder..
Trotzdem allen viel Glück mit den Dingern - ich wünsche euch die 10000% !!
AUF GEHT`S
Magere knappe 3% im Plus bei 0,07.
Das ist das Problem bei CALY, wenn die gute News bringen, geht´s eigentlich selten richtig gut ab und nach 2-3 Tagen stehen die wie vorher auch.
Unter 0,05 kaufe ich wieder..
Trotzdem allen viel Glück mit den Dingern - ich wünsche euch die 10000% !!
AUF GEHT`S
bei den News müßte es doch nu langsam aufwärts gehen oder.
also auf gehts
gruß grenke
also auf gehts
gruß grenke
Calypte Biomedical Corp. (ticker: CALY, exchange: NASDAQ) News Release - 10-Jan-2003
--------------------------------------------------
J. Richard George, CDC and HIV Veteran Joins Calypte as VP of Government Affairs
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 10, 2003--
HIV and Infectious Diseases Expert Now Responsible for Calypte's
Expanding Global Government Relations Programs
Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot supplemental test, today announced that Dr. Richard George has joined Calypte as Vice President of Government Affairs. In this newly created position, Dr. George will be responsible for working with a variety of public sector and government-sponsored agencies around the world to increase awareness of the importance of HIV testing, highlight the benefits of urine-based testing, develop HIV testing programs and secure capital to fund programs.
Prior to joining Calypte, Dr. George worked for OraSure Technologies, Inc. (Nasdaq:OSUR) as Senior Vice President of Research and Development for infectious diseases. During his tenure at OraSure, he supervised the successful development of the recently FDA-approved OraQuick Rapid HIV-1 blood test, including product development, product support, and clinical trials. Previously, he was Chief Scientific Officer for Epitope, Inc., now OraSure, where he was responsible for all scientific programs relating to new products including those focused on testing for HIV/AIDS.
Prior to joining Epitope, Dr. George spent 34 years at the U.S. Centers for Disease Control and Prevention (CDC) in positions of increasing responsibility, most recently serving as the Chief of Developmental Technology Section in the AIDS Program where he provided laboratory support and coordination for the CDC's international HIV/AIDS projects. These projects included maintaining global surveillance of emerging strains of HIV, conducting tests on genetic variations of HIV, and developing new antibody-based methods for identifying HIV strains. Dr. George used the results of his efforts to collaborate with such entities as the World Health Organization (WHO), and the Pan American Health Organization (PAHO), to strive for standardized HIV testing in developing countries.
"We are thrilled to have a professional of Richard's caliber join Calypte, and his scientific and global government relations expertise will prove invaluable to our team," stated Nancy Katz, president and CEO of Calypte. "We look forward to significant progress in securing relationships with several influential organizations to demonstrate the merits of our urine-based HIV tests. His career and core competency in HIV at the CDC and at OraSure will propel a dynamic synergy in advancing relations between Calypte, government agencies and global health organizations."
Dr. George is a past and present member of several scientific societies such as the American Society of Microbiology and continues to be a consultant to the WHO and the University of Pennsylvania. He has won numerous awards for scientific excellence throughout his career, has more than 100 scientific publications to his credit and has served as a Scientific Reviewer for the international journal AIDS and the Journal of Medical Virology.
--------------------------------------------------
J. Richard George, CDC and HIV Veteran Joins Calypte as VP of Government Affairs
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 10, 2003--
HIV and Infectious Diseases Expert Now Responsible for Calypte's
Expanding Global Government Relations Programs
Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot supplemental test, today announced that Dr. Richard George has joined Calypte as Vice President of Government Affairs. In this newly created position, Dr. George will be responsible for working with a variety of public sector and government-sponsored agencies around the world to increase awareness of the importance of HIV testing, highlight the benefits of urine-based testing, develop HIV testing programs and secure capital to fund programs.
Prior to joining Calypte, Dr. George worked for OraSure Technologies, Inc. (Nasdaq:OSUR) as Senior Vice President of Research and Development for infectious diseases. During his tenure at OraSure, he supervised the successful development of the recently FDA-approved OraQuick Rapid HIV-1 blood test, including product development, product support, and clinical trials. Previously, he was Chief Scientific Officer for Epitope, Inc., now OraSure, where he was responsible for all scientific programs relating to new products including those focused on testing for HIV/AIDS.
Prior to joining Epitope, Dr. George spent 34 years at the U.S. Centers for Disease Control and Prevention (CDC) in positions of increasing responsibility, most recently serving as the Chief of Developmental Technology Section in the AIDS Program where he provided laboratory support and coordination for the CDC's international HIV/AIDS projects. These projects included maintaining global surveillance of emerging strains of HIV, conducting tests on genetic variations of HIV, and developing new antibody-based methods for identifying HIV strains. Dr. George used the results of his efforts to collaborate with such entities as the World Health Organization (WHO), and the Pan American Health Organization (PAHO), to strive for standardized HIV testing in developing countries.
"We are thrilled to have a professional of Richard's caliber join Calypte, and his scientific and global government relations expertise will prove invaluable to our team," stated Nancy Katz, president and CEO of Calypte. "We look forward to significant progress in securing relationships with several influential organizations to demonstrate the merits of our urine-based HIV tests. His career and core competency in HIV at the CDC and at OraSure will propel a dynamic synergy in advancing relations between Calypte, government agencies and global health organizations."
Dr. George is a past and present member of several scientific societies such as the American Society of Microbiology and continues to be a consultant to the WHO and the University of Pennsylvania. He has won numerous awards for scientific excellence throughout his career, has more than 100 scientific publications to his credit and has served as a Scientific Reviewer for the international journal AIDS and the Journal of Medical Virology.
Freitags soll man ja Lottospielen oder ?
gruß Grenke
gruß Grenke
auch die erstern käufer - ich denke, dass die Amis diese Meldung entsprechend honorieren werden und heute bestimmt noch ein paar Prozent drin sind.
B.
B.
im falschen Aufzug. Das geht ja erschreckend (rasend ) nach unten !!!
gruß hannes
gruß hannes
und der beabsichtigte Reverse Split,am 14. 2. Hauptversammlung
ragingbull.lycos.com/mboard/boards.cgi?board=CALY&read=4378
www.pinksheets.com/quote/filings.jsp?symbol=CALY
denke mal die sind wirklich fast pleite und wenn sie jetzt den Markt mit den Optionen überschwemmen,wird das nichts bessern ausser momentan
ragingbull.lycos.com/mboard/boards.cgi?board=CALY&read=4378
www.pinksheets.com/quote/filings.jsp?symbol=CALY
denke mal die sind wirklich fast pleite und wenn sie jetzt den Markt mit den Optionen überschwemmen,wird das nichts bessern ausser momentan
je das ist es ja gerade, alle denken das die fast pleite sind, daher auch dieser kurs.
Aber was passiert wenn die nu doch nicht pleite sind, genau das ist ja mein gedanke dabei, alles oder nichts.
gruß grenke
Aber was passiert wenn die nu doch nicht pleite sind, genau das ist ja mein gedanke dabei, alles oder nichts.
gruß grenke
0,060 geh ich nochmals rein. Wer nicht wagt, der nicht gewinnt !
gruß hannes
gruß hannes
calypte sollte eigentlich schon bei 50 cent stehen u. weil sie das nicht tut, macht mich das mega-stutzig.
Kann mir einer den kurs erklären? Nur pos. News u. der kurs hängt bei 6 cent.
Kann mir einer den kurs erklären? Nur pos. News u. der kurs hängt bei 6 cent.
Hab mir nochmals 50.000 zugelegt. Jetzt noch ein paar gute News und Ende nächster Woche stehen die wieder bei 0,070. Macht saubere 40% .
gruß hannes
gruß hannes
Die Aktie hat nach den Abgaben der letzten Wochen einigen Erholungsbedarf, würde mich nicht wundern, wenn da die nächsten Tage ein Kursfeuerwerk abgeht!
Euer masteruz
Euer masteruz
Calypte Biomedical Corp. has added a News Release to its Investor Relations web site.
Title: Calypte HIV-1 Urine Tests Used in Study Led by Johns Hopkins for HIV Testing in High Risk Communities; Study Concluded Urine Tests are Effective Tools for HIV Screening
Date: 1/27/2003 7:00:00 AM
gruß grenke
Title: Calypte HIV-1 Urine Tests Used in Study Led by Johns Hopkins for HIV Testing in High Risk Communities; Study Concluded Urine Tests are Effective Tools for HIV Screening
Date: 1/27/2003 7:00:00 AM
gruß grenke
mal wieder nen Spurt zu sehen?Also am 14.02 kommen Zahlen,mal schaun wie die Aussehen.
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem CALYPTE BIOMED. DL-.001 Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 90 | Caly`s Explosion | calyritter | Dr.UdoBroemme | 29.02.20 22:49 | ||
| 34 | Ein Impfstoff fürs Depot! | Gruenspan | 1Quantum | 31.05.18 09:30 | ||
| 83 | an die CALY (CYPTV)-Fans/Kritiker/Besitzer | Kalli2003 | Kalli2003 | 13.08.05 02:01 | ||
| 1.625 | Entweder 10000% oder Totalverlust | grenke | grenke | 13.11.03 22:55 | ||
| 12 | Wir werden sehen | Nukem | standingovation | 15.08.03 16:39 |